Skip to main content

Volume 12 Supplement 2

Advanced breast cancer therapy


Edited by Jenny Chang

Publication of this supplement has been sponsored by Bristol Myers Squibb Company. Translation services and administrative support was provided to the authors by Thomson Reuters, Healthcare and Science.

  1. Perou's molecular classification defines tumors that neither express hormone receptors nor overexpress HER2 as triple-negative (TN) tumors. These tumors account for approximately 15% of breast cancers. The so-...

    Authors: Reinaldo D Chacón and María V Costanzo
    Citation: Breast Cancer Research 2010 12(Suppl 2):S3

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.4 - 5-year Impact Factor
    1.764 - SNIP (Source Normalized Impact per Paper)
    2.408 - SJR (SCImago Journal Rank)

    2023 Speed
    20 days submission to first editorial decision for all manuscripts (Median)
    129 days submission to accept (Median)

    2023 Usage 
    1,561 Altmetric mentions